Skip to Content
Stock Analyst Update

Bayer Stock Getting Punished, Shares Undervalued

Litigation concerns about glyphosate weedkillers are weighing on Bayer's shares, but we don't expect to make a significant change to our fair value estimate.


The multimillion-dollar verdict on Aug. 10 against Monsanto over glyphosate weedkillers, including the Roundup brand, is concerning for  Bayer (BAYRY), which acquired the company in June, but we don’t expect a major change to our fair value estimate. Bayer is appealing the ruling. If there are other lawsuits, they are likely to be litigated slowly, over many years, and, historically in cases like these, the final results tend to be more minor than the initial cases.

The Roundup product line makes up a small portion of Bayer’s revenue and profits. Based on pro forma numbers from the two companies, we estimate that glyphosate, the chemical used in the Roundup brand, would account for less than 10% of Bayer’s total sales and even less of Bayer’s profits. For context, we expect all of the crop science segment to make up about 44% of Bayer's total revenue in 2019.

Bayer does not break out glyphosate-specific sales, but in 2017, herbicides accounted for just 7.5% of total sales. We note that Bayer did have to divest some of its glyphosate assets (to BASF) to complete the Monsanto acquisition. Glyphosate has been off patent for nearly two decades, and margins are likely on the lower end of Bayer’s crop chemicals. Based on this, we believe glyphosate accounted for a low-single-digit percentage of Bayer’s profits.

In 2017, Monsanto’s crop chemicals segment, called agricultural productivity, accounted for around 25% of total sales, but only 11% of profits. Monsanto, like Bayer, did not break out specific brands, but it sold only two major crop chemicals: glyphosate (under the Roundup brand) and dicamba. The majority of Monsanto’s crop chemicals profits were from glyphosate, so we estimate Roundup profits to be 8%-9% of Monsanto’s total profits.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Damien Conover does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.